Availability of Semaglutide (Ozempic®)

On Friday, 1 September, the Department of Health, Health Products Regulatory Authority (HPRA), Pharmaceutical Society of Ireland (PSI), Medical Council and various partners across the Health Service Executive (HSE) issued the following message in relation to Ozempic® availability.

HSE-PCRS has confirmed that reimbursement support for the 0.25mg and 0.5mg pen presentations of Ozempic® to make up a 1mg dose is not approved under the Community Drug Schemes or any other HSE arrangement.